Literature DB >> 18836556

Nutraceuticals in Prostate Disease: The Urologist's Role.

J Curtis Nickel, Daniel Shoskes, Claus G Roehrborn, Mark Moyad.   

Abstract

Interest in and use of complementary and alternative therapies, especially nutraceuticals, is high in prostate disease. These therapies have shown potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer. Some have produced results equal to or better than pharmaceuticals currently prescribed for BPH. In category III prostatitis, some nutraceuticals may offer relief to patients who get little from standard therapy. Because it is becoming apparent that inflammation may play a role in the progression of BPH and development of prostate cancer, nutraceuticals, which commonly have anti-inflammatory properties, may play a role. These therapies have also shown potential in prostate cancer treatment and prevention, especially those that also reduce cardiovascular events or risk. Nevertheless, uses of some nutraceuticals in prostate disease have had less desirable consequences, showing lack of efficacy, adulteration, and/or severe side effects or drug interactions. By ensuring that these therapies undergo careful study for effectiveness, quality, and safety, urologists can look forward to adding them to their evidence-based armamentarium for prostate disease.

Entities:  

Keywords:  Benign prostatic hyperplasia; Complementary or alternative medical therapy; Nutraceuticals; Prostate cancer; Prostatitis

Year:  2008        PMID: 18836556      PMCID: PMC2556486     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  112 in total

Review 1.  Complementary and alternative medicine in urology.

Authors:  Kurt Dreikorn
Journal:  BJU Int       Date:  2005-12       Impact factor: 5.588

2.  Effects of cranberry juice on uropathogenic Escherichia coli in vitro biofilm formation.

Authors:  P Di Martino; R Agniel; J L Gaillard; P Denys
Journal:  J Chemother       Date:  2005-10       Impact factor: 1.714

3.  The so-called "placebo effect" in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring.

Authors:  S M Sech; J D Montoya; P A Bernier; E Barnboym; S Brown; A Gregory; C G Roehrborn
Journal:  Urology       Date:  1998-02       Impact factor: 2.649

4.  Intensive lifestyle changes may affect the progression of prostate cancer.

Authors:  Dean Ornish; Gerdi Weidner; William R Fair; Ruth Marlin; Elaine B Pettengill; Caren J Raisin; Stacey Dunn-Emke; Lila Crutchfield; F Nicholas Jacobs; R James Barnard; William J Aronson; Patricia McCormac; Damien J McKnight; Jordan D Fein; Ann M Dnistrian; Jeanmaire Weinstein; Tung H Ngo; Nancy R Mendell; Peter R Carroll
Journal:  J Urol       Date:  2005-09       Impact factor: 7.450

5.  Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group.

Authors:  R R Berges; J Windeler; H J Trampisch; T Senge
Journal:  Lancet       Date:  1995-06-17       Impact factor: 79.321

6.  Prostatic antibacterial factor. Identity and significance.

Authors:  W R Fair; J Couch; N Wehner
Journal:  Urology       Date:  1976-02       Impact factor: 2.649

7.  A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome.

Authors:  Steven A Kaplan; Michael A Volpe; Alexis E Te
Journal:  J Urol       Date:  2004-01       Impact factor: 7.450

8.  Cytokine polymorphisms in men with chronic prostatitis/chronic pelvic pain syndrome: association with diagnosis and treatment response.

Authors:  Daniel A Shoskes; Qussay Albakri; Kim Thomas; Daniel Cook
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

9.  Natural history of early, localized prostate cancer.

Authors:  Jan-Erik Johansson; Ove Andrén; Swen-Olof Andersson; Paul W Dickman; Lars Holmberg; Anders Magnuson; Hans-Olov Adami
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

10.  The NIH Consensus concept of chronic prostatitis/chronic pelvic pain syndrome compared with traditional concepts of nonbacterial prostatitis and prostatodynia.

Authors:  John N Krieger; Susan O Ross; Leslie Deutsch; Donald E Riley
Journal:  Curr Urol Rep       Date:  2002-08       Impact factor: 2.862

View more
  10 in total

1.  [S2e guideline of the German urologists: Conservative and pharmacologic treatment of benign prostatic hyperplasia].

Authors:  K Höfner; T Bach; R Berges; K Dreikorn; C Gratzke; S Madersbacher; M-S Michel; R Muschter; M Oelke; O Reich; C Tschuschke; T Bschleipfer
Journal:  Urologe A       Date:  2016-02       Impact factor: 0.639

2.  [Phytotherapy for benign prostatic hyperplasia].

Authors:  Friedemann Zengerling
Journal:  Urologe A       Date:  2018-07       Impact factor: 0.639

3.  Management of experimental benign prostatic hyperplasia in rats using a food-based therapy containing Telfairia occidentalis seeds.

Authors:  Chukwunonso E C C Ejike; Lawrence U S Ezeanyika
Journal:  Afr J Tradit Complement Altern Med       Date:  2011-06-01

4.  Chemical proteomics identifies heterogeneous nuclear ribonucleoprotein (hnRNP) A1 as the molecular target of quercetin in its anti-cancer effects in PC-3 cells.

Authors:  Chia-Chen Ko; Yun-Ju Chen; Chih-Ta Chen; Yu-Chih Liu; Fong-Chi Cheng; Kai-Chao Hsu; Lu-Ping Chow
Journal:  J Biol Chem       Date:  2014-06-24       Impact factor: 5.157

5.  Complementary and alternative therapies for urinary symptoms: use in a diverse population sample qualitative study.

Authors:  Courtney B Jackson; Simone P Taubenberger; Elizabeth Botelho; Journel Joseph; Sharon L Tennstedt
Journal:  Urol Nurs       Date:  2012 May-Jun

Review 6.  [Influence of medical BPS treatment on sexual function].

Authors:  T Bschleipfer; M Burkart
Journal:  Urologe A       Date:  2018-12       Impact factor: 0.639

Review 7.  Management of Benign Prostatic Hyperplasia: Could Dietary Polyphenols Be an Alternative to Existing Therapies?

Authors:  Chinedum Eleazu; Kate Eleazu; Winner Kalu
Journal:  Front Pharmacol       Date:  2017-04-28       Impact factor: 5.810

8.  Attenuation of Benign Prostatic Hyperplasia by Optimized Tadalafil Loaded Pumpkin Seed Oil-Based Self Nanoemulsion: In Vitro and In Vivo Evaluation.

Authors:  Nabil A Alhakamy; Usama A Fahmy; Osama A A Ahmed
Journal:  Pharmaceutics       Date:  2019-12-01       Impact factor: 6.321

9.  D-004 ameliorates phenylephrine-induced urodynamic changes and increased prostate and bladder oxidative stress in rats.

Authors:  Ambar Oyarzábal; Yohani Pérez; Vivian Molina; Rosa Mas; Yazmin Ravelo; Sonia Jiménez
Journal:  Transl Androl Urol       Date:  2015-08

10.  Endogenous Sphingolipid Signaling Pathway Implicated in the Action of Croton membranaceus on the Prostate Gland in BPH Patients.

Authors:  George Awuku Asare; Yvonne Anang; Daniel K Afriyie; Brodrick Yeboah Amoah; Bernice Asiedu; Derek Doku; Hannah Serwah Ocansey; Nana Yaw Odei Danso; Prince Tekpor; Sarah Osam
Journal:  Medicines (Basel)       Date:  2017-11-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.